Millendo Therapeutics Stock

MLND

US60040X1037

Biotechnology & Medical Research

Latest news : Millendo Therapeutics

11/05/23	Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
30/12/22	Millendo Therapeutics, Inc. and Tempest Therapeutics, Inc. Enter into First Amendment to Loan and Security Agreement	CI
30/09/21	Millendo Therapeutics, Inc. Joins Nicholas Maestas as Vice President, Strategy and Finance and It's Principal Financial Officer	CI
25/06/21	Millendo Therapeutics, Inc.(NasdaqCM:MLND) dropped from NASDAQ Composite Index	CI
25/06/21	Tempest Therapeutics Inc. completed the acquisition of Millendo Therapeutics, Inc. in a reverse merger transaction for approximately $180 million.	CI
23/06/21	Millendo Therapeutics : , Tempest Therapeutics Investors Approve Merger Proposals	MT
13/05/21	Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	CI
29/03/21	Millendo Therapeutics, Inc., Tempest Therapeutics Inc. - M&A Call
29/03/21	Millendo Therapeutics : Tempest, Millendo Agree to Merge, Combined Company to List on NASDAQ	MT
29/03/21	Millendo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	CI
29/03/21	Tempest Therapeutics Inc. entered into a definitive agreement and plan of merger to acquire Millendo Therapeutics, Inc. in a reverse merger transaction.	CI
28/01/21	Millendo Therapeutics, Inc. Announces Executive Changes	CI
28/01/21	Millendo Therapeutics, Inc. Plans to Reduce Its Workforce with Majority of Reduction in Personnel Expects to Complete by April 15, 2021	CI

More news

Analysts' recommendations: Millendo Therapeutics

06/01/21	MILLENDO THERAPEUTICS : Ladenburg Thalmann Downgrades Millendo Therapeutics to Neutral from Buy	MT
06/01/21	MILLENDO THERAPEUTICS : SVB Leerink Downgrades Millendo Therapeutics to Market Perform From Outperform; Price Target is $2	MT
10/11/20	MILLENDO THERAPEUTICS : Wedbush Adjusts Price Target for Millendo Therapeutics to $2 From $3, Maintains Neutral Rating	MT

More recommendations

Press Releases: Millendo Therapeutics

24/07/21	TEMPEST THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
17/07/21	Tempest Therapeutics : BUSINESS (Form 8-K)	PU
17/07/21	TEMPEST THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
12/07/21	Tempest Therapeutics : to Participate in William Blair 2021 Biotech Focus Conference	AQ
12/07/21	TEMPEST THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ

More press releases

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MILLENDO THERAPEUTICS	-14.88%	+3.21%	-	-	303M
LONZA GROUP AG	+2.08%	-0.99%	-1.03%	+11.57%	46.86B
REVOLUTION MEDICINES, INC.	-0.67%	+4.42%	+405.54%	+648.37%	40.23B
BEONE MEDICINES AG	+0.41%	+5.52%	+11.27%	+56.42%	36.23B
IQVIA HOLDINGS INC.	+1.76%	+3.90%	+7.12%	-5.66%	34.72B
CELLTRION, INC.	+0.62%	+1.65%	+5.41%	+43.89%	27.89B
MEDPACE HOLDINGS, INC.	-0.56%	+13.05%	+31.73%	+139.79%	16.79B
ASCENDIS PHARMA A/S	+0.41%	+1.23%	-	-	16.74B
EUROFINS SCIENTIFIC SE	+0.78%	-5.88%	+2.29%	+7.76%	13.12B
ICON PUBLIC LIMITED COMPANY	+2.06%	+2.19%	-10.46%	-29.72%	12.7B
Average	-0.84%	+0.97%	+56.49%	+109.05%	27.25B
Weighted average by Cap.	+0.71%	+1.05%	+76.59%	+139.01%

See all sector performances

Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.

Employees

Sector

Biotechnology & Medical Research

More about the company